Clal Insurance’s Lam Research LRCX Stock Holding History

Clal Insurance’s Portfolio LRCX Stock Details LRCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5,400	Closed	-$2.24M	–	212
2025 Q1	$2.24M	Buy	+5,400	New	+$425K	0.02%	84

Other funds holding LRCX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Clal Insurance's LRCX Position: Q2 2026 in Review

Clal Insurance reduced its Lam Research (LRCX) stake by 0% in Q2 2026, selling an estimated $2.73K and leaving 346,052 shares worth $150M. The position accounts for 0.67% of the portfolio, ranked #35.

Clal Insurance first reported a position in LRCX in Q4 2023 and has held it in 8 quarters since. 3,137 funds tracked by Wall St. Rank hold LRCX as of Q2 2026.

Clal Insurance held 346,052 shares of Lam Research worth $150M as of Q2 2026.
Clal Insurance sold 9 Lam Research shares in Q2 2026, an estimated $2.73K.
Lam Research made up 0.67% of Clal Insurance's portfolio in Q2 2026, its #35 holding.
Clal Insurance first reported a position in Lam Research in Q4 2023 and has held it in 8 quarters since.
3,137 funds tracked by Wall St. Rank held Lam Research as of Q2 2026.

Based on Clal Insurance's 13F filing for Q2 2026, filed 13 Aug 2026.